Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ecke

Showing results (301-310 of 523) with videos related to

Pageof 53
Sort By:
Anti-Cancer Drugs|February 15, 2013
Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapyHolger Gerullis, Christoph Eimer, Thorsten H Ecke, et al.
Agents and Actions. Supplements|January 1, 1992
Possible identity of kallikrein binding protein with protein C inhibitorS Ecke, M Geiger, I Resch, et al.
ORL; Journal for Oto-Rhino-Laryngology and Its Related Specialties|July 1, 1997
Selective chemical vestibulectomy. Preliminary resultsU Ecke, K Begall, R G Amedee, et al.
Cells|August 22, 2019
Tissue Specific Differentiation of Human Chondrocytes Depends on Cell Microenvironment and Serum SelectionAnnemarie Ecke, Anne-Helen Lutter, Jenny Scholka, et al.
Environmental Science & Technology|October 10, 2015
Impact of Beaver Pond Colonization History on Methylmercury Concentrations in Surface WaterOded Levanoni, Kevin Bishop, Brendan G Mckie, et al.
Journal of the Egyptian Society of Parasitology|January 28, 2011
What happens if nothing happens?--History of an untreated urothelial carcinoma of the bladderH Gerullis, T H Ecke, M Wishahi, et al.
Urologic Oncology|March 28, 2008
Complications and risk factors of transrectal ultrasound guided needle biopsies of the prostate evaluated by questionnaireThorsten H Ecke, Sven Gunia, Peter Bartel, et al.
Anticancer Research|April 9, 2005
Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutationThorsten H Ecke, Horst H Schlechte, Guntram Schulze, et al.
Journal of Molecular Medicine (Berlin, Germany)|September 1, 1996
Regulation of epithelial ion channels by the cystic fibrosis transmembrane conductance regulatorR Greger, M Mall, M Bleich, et al.
Urologic Oncology|March 28, 2008
Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancerThorsten H Ecke, Horst H Schlechte, Sven Gunia, et al.
Pageof 53

Showing results (301-310 of 523) with videos related to

Sort By:
Pageof 53
Anti-Cancer Drugs|February 15, 2013
Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapyHolger Gerullis, Christoph Eimer, Thorsten H Ecke, et al.
Agents and Actions. Supplements|January 1, 1992
Possible identity of kallikrein binding protein with protein C inhibitorS Ecke, M Geiger, I Resch, et al.
ORL; Journal for Oto-Rhino-Laryngology and Its Related Specialties|July 1, 1997
Selective chemical vestibulectomy. Preliminary resultsU Ecke, K Begall, R G Amedee, et al.
Cells|August 22, 2019
Tissue Specific Differentiation of Human Chondrocytes Depends on Cell Microenvironment and Serum SelectionAnnemarie Ecke, Anne-Helen Lutter, Jenny Scholka, et al.
Environmental Science & Technology|October 10, 2015
Impact of Beaver Pond Colonization History on Methylmercury Concentrations in Surface WaterOded Levanoni, Kevin Bishop, Brendan G Mckie, et al.
Journal of the Egyptian Society of Parasitology|January 28, 2011
What happens if nothing happens?--History of an untreated urothelial carcinoma of the bladderH Gerullis, T H Ecke, M Wishahi, et al.
Urologic Oncology|March 28, 2008
Complications and risk factors of transrectal ultrasound guided needle biopsies of the prostate evaluated by questionnaireThorsten H Ecke, Sven Gunia, Peter Bartel, et al.
Anticancer Research|April 9, 2005
Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutationThorsten H Ecke, Horst H Schlechte, Guntram Schulze, et al.
Journal of Molecular Medicine (Berlin, Germany)|September 1, 1996
Regulation of epithelial ion channels by the cystic fibrosis transmembrane conductance regulatorR Greger, M Mall, M Bleich, et al.
Urologic Oncology|March 28, 2008
Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancerThorsten H Ecke, Horst H Schlechte, Sven Gunia, et al.
Pageof 53